Latest in Cardiology from ACC.org

• SIMPLAAFY: Reduced-Dose NOACs, Aspirin Alone Noninferior to DAPT Following LAAC
  Reduced-dose non-vitamin K oral anticoagulants (NOACs) as well as aspirin alone were noninferior to dual antiplatelet therapy (DAPT) for a composite of adverse clinical outcomes through six months following left atrial appendage closure (LAAC), according to results from the SIMPLAAFY trial...
• PROGRESS: TAVR Superior to Clinical Surveillance in Patients With Moderate AS With At-Risk Features
  In patients with moderate aortic stenosis (AS) and at least one at-risk feature, earlier TAVR lowered the incidence of death or heart failure (HF) event, reduced HF hospitalizations and improved quality of life at two years compared to clinical surveillance, according to findings from the PROGRESS trial presented at TCT 2026 and simultaneously published in […]
• hs-CRP in Cardiovascular Risk Assessment: A Practical Guide in2026
  This episode is part of ACC’s ongoing effort to advance understanding of inflammation and its role in cardiovascular risk assessment.
• Cost-Effectiveness of Early TAVR; TR and Mortality; Superiority of Tricuspid Repair
  New late-breaking research presented at TCT 2026 highlights the cost-effectiveness of early TAVR in asymptomatic severe aortic stenosis (AS), the association between increasing tricuspid regurgitation (TR) severity and mortality, and the benefits of transcatheter tricuspid valve repair.
• VERITAS and TRAVEL III: LAAO With Amulet 360; TTVR With LuX-Valve Plus System
  Among patients who underwent left atrial appendage occlusion (LAAO) with the Amulet 360 device, complete LAA closure was observed in 96.3% of patients at one year with low rates of stroke and mortality, according to results from the VERITAS trial, presented at TCT 2026 and simultaneously published in JACC: Cardiovascular Interventions.